Clinical Trial Update: Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Olaptesed (NOX-A12) alone and with pembrolizumab in metastatic colorectal and pancreatic cancer has completed Phase 1/2 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Pancreatic Cancer

Drugs mentioned

• Olaptesed (NOX-A12)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: TME Pharma AG | Conditions: Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED